Benzinga | Dec 21, 2021 10:01AM EST

JP Morgan Maintains Neutral on Biogen, Lowers Price Target to $276

JP Morgan analyst Cory Kasimov maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $324 to $276.